They believe that the REIT's recent unit price correction is an attractive re-entry point. At current levels, the unit price implies an attractive forward FY2026 yield of 5.0%.
DBS Group Research has kept its "buy" call and raised its target price for Parkway Life REIT to $4.80 from $4.50, calling the owner of hospitals and nursing homes "a rare jewel" among S-REITs offering "highly visible, stable and sustainable offerings."
In their Nov 25 note, analysts Tabitha Foo and Derek Tan laud the REIT's position in a resilient industry along with long leases with downside risk protection.
